February industry-round up: Trinity Life Sciences launches new solution in the Patient Centricity Center of Excellence
This month, Trinity Life Sciences (MA, USA) launched a new integrated patient focus solution as part of their Patient Centricity Center of Excellence, The Canadian Neuromuscular Disease Registry (CNDR; Calgary, Canada) and Amylyx Pharmaceuticals (MA, USA) have started collaborating to improve outcomes in ALS, Calyx EDC (NC, USA) has been chosen to collect RWD for a late phase trial and Infor (NY, USA) have partnered with Syapse (CA, USA) to improve cancer care services using their cloud-based services.
In this latest instalment of our regular monthly column, we summarize a selection of key real-world evidence (RWE)-focused industry developments that have taken place over the past month.
The news highlights:
-
- Trinity Life Sciences launches integrated patient focus as part of the Patient Centricity Center of Excellence
- The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals partner up to improve outcomes for ALS patients
- Calyx EDC steps up to collect RWE in a late phase trial
- Infor teams up with Syapse to provide high-quality cancer care
Trinity Life Sciences launches integrated patient focus as part of the Patient Centricity Center of Excellence
Trinity Life Sciences (MA, USA), a provider of life science solutions globally, has launched new integrated patient focus solutions as part of their Patient Centricity Center of Excellence, founded in 2019. This integrated approach will allow researchers to gain patient insights with a multi-stakeholder perspective. The patient journey is said to be an important part of life sciences and is possible with study design and analysis methods that meet these high standards. This can include leveraging the benefits of a real-world evidence (RWE) study.
Jennifer Parr, Principal and Head of Patient Centricity at Trinity Life Sciences, highlighted the importance of offering these services, as their “methodology allows for a multidimensional view of clinical patient flow, physical logistics, financial and access hurdles, emotional experience and information needs.”
The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals partner up to improve outcomes for ALS patients
The CNDR (Calgary, Canada) and Amylyx Pharmaceuticals (MA, USA) have announced a collaboration to generate RWE on the investigational therapy AMX0035 in order to treat amyotrophic lateral sclerosis (ALS). Neuromuscular centers across Canada will reach out to willing participants and collect longitudinal real-world data on the efficacy of AMX0035. This partnership is the first opportunity to generate meaningful RWE for further research.
Lawrence Korngut, Principal Investigator of CNDR reinforced the benefit of maintaining real-world data registries, as “the advantage of CNDR is that it enables the generation of real‐world evidence for decision‐making, while prioritizing patient treatment and access to investigational therapy. We hope that with this partnership, we can provide insights and guidance for best practices in ALS treatment.”
Calyx EDC steps up to collect RWE in a late phase trial
Calyx EDC (NC, USA), an eClinical and Regulatory solutions provider, has announced that its electronic data capture (EDC) system has been chosen by the pharmaceutical industry to collect RWD for a global, lengthy, late phase study. In a press release, Calyx EDC stated that their electronic services had been selected due to its proven effectiveness in collating clinical trial data. Moreover, Calyx are suggested to have the ability to deliver the RWD reliably and cost-effectively to meet the needs of the pharmaceutical industry, which also included continuous data collection.
“We’re thrilled to work with this leading pharmaceutical company and to extend our 30 years’ experience in delivering reliable, high-quality data to help them fully understand the long-term effects of their medical products.” stated Juan Munoz-Pujol, Vice President of IRT and EDC at Calyx EDC.
Infor teams up with Syapse to provide high-quality cancer care
Infor (NY, USA), the industry cloud company, has announced that Syapse’s (CA, USA) use of their Infor CloudSuite Cloverleaf services has been beneficial to refine and extract RWD in spite of typical challenges. They have suggested that Syapse were still able to generate RWE through disparate data sources, utilizing Infor’s services to prioritize scalability and boost privacy and security. Syapse required the high-quality services of Infor to help collect, analyze and leverage RWD, which will go on to have significant impact on the healthcare industry and patients.
Infor executive Vice President, Matt Breslin, shared his thoughts on the collaboration. “Partnering with a leading organization like Syapse is exciting for us because together, we can directly impact treatment and lead the industry in providing real-world evidence that empowers better care.”
